Previous 10 | Next 10 |
Arrowhead Pharmaceuticals ( ARWR ) - The company announced that dosing has begun in a new triple combination cohort utilizing JNJ-3989 plus additional undisclosed agents in the ongoing phase 1/2 study in patients with chronic hepatitis B virus. As a result of opening this new cohort, Arrowhe...
BOTHELL, Wash., April 23, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will present additional analyses of the efficacy and qualit...
The FDA accepts for review Alder BioPharmaceuticals' (NASDAQ: ALDR ) marketing application seeking approval for eptinezumab for the prevention of migraine. More news on: Alder BioPharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
BOTHELL, Wash., April 22, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that the U.S. Food and Drug Administration (FDA) has accepted for r...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Another nice ramp-up of earnings arrives next week to keep investors busy. All told...
BOTHELL, Wash., April 08, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced the appointment of Nadia Dac as chief commercial officer (CCO), eff...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees a heavy dose of healthcare companies presenting at investor con...
BOTHELL, Wash., April 02, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that members of the management team will provide a business overview...
News, Short Squeeze, Breakout and More Instantly...
Alder BioPharmaceuticals Inc. Company Name:
ALDR Stock Symbol:
NASDAQ Market:
Alder BioPharmaceuticals Inc. Website:
Biotech is in the doldrums. The SPDR S&P Biotech ETF declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...
BOTHELL, Wash., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing therapeutic antibodies for the treatment of migraine, today announced dosing of the first patient in a Phase 1 clinical study to evaluate ALD191...
Shares of Alder Biopharmaceuticals (NASDAQ: ALDR) jumped 111% in September, according to data provided by S&P Global Market Intelligence , after the biotech said it will be acquired by Lundbeck. Lundbeck, a fairly large drugmaker in Denmark, is after Alder Pharmaceuticals' migraine m...